Trial Profile

A Phase 2 Trial of the MEK Inhibitor PD-0325901 in Adolescents and Adults With NF1-Associated Morbid Plexiform Neurofibromas

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 07 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirdametinib (Primary)
Indications Neurofibromatosis 1; Plexiform neurofibroma
Focus Therapeutic Use
Acronyms NF-106

Most Recent Events

27 Sep 2022 Results to develop a population pharmacokinetic / pharmacodynamic model for mirdametinib and to describe the exposure response relationship, presented at the 2022 American College of Clinical Pharmacology Annual Meeting.
28 Jan 2021 Results published in the Journal of Clinical Oncology.
30 Jul 2019 According to a SpringWorks Therapeutics media release, this trial was conducted by the Neurofibromatosis Clinical Trial Consortium.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com